

# Zhi-hui Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2209011/publications.pdf>

Version: 2024-02-01

93  
papers

1,814  
citations

279798

23  
h-index

330143

37  
g-index

102  
all docs

102  
docs citations

102  
times ranked

2274  
citing authors

#	ARTICLE	IF	CITATIONS
1	Panâ€cancer analysis identifies <sc><i>CD300</i></sc> molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. <i>Cancer Medicine</i> , 2023, 12, 789-807.	2.8	5
2	Reduced expression of lncRNA <i>DLEU7-AS1</i> is a novel favorable prognostic factor in acute myeloid leukemia. <i>Bioscience Reports</i> , 2022, 42, .	2.4	1
3	Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2021, 13, 16.	4.1	11
4	Abnormal expression and methylation of PRR34â€AS1 are associated with adverse outcomes in acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 5283-5296.	2.8	4
5	Clinical and prognostic relevance of <i>CXCL12</i> expression in acute myeloid leukemia. <i>PeerJ</i> , 2021, 9, e11820.	2.0	2
6	Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 717527.	4.8	16
7	Expression characteristic of <i>4lg B7-H3</i> and <i>2lg B7-H3</i> in acute myeloid leukemia. <i>Bioengineered</i> , 2021, 12, 11987-12002.	3.2	5
8	Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial. <i>Haematologica</i> , 2020, 105, e29-e32.	3.5	15
9	Hypomethylation of MIRâ€378 5â€™â€flanking region predicts poor survival in young patients with myelodysplastic syndrome. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2020, 8, e1067.	1.2	2
10	EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1640-1649.	3.6	8
11	Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. <i>Cell Death and Disease</i> , 2020, 11, 997.	6.3	18
12	Identification and validation of prognosisâ€related <i>DLX5</i> methylation as an epigenetic driver in myeloid neoplasms. <i>Clinical and Translational Medicine</i> , 2020, 10, e29.	4.0	24
13	A three-gene signature might predict prognosis in patients with acute myeloid leukemia. <i>Bioscience Reports</i> , 2020, 40, .	2.4	3
14	Methylation-independent expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 4840-4852.	0.0	0
15	Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine. <i>Cancer Cell International</i> , 2019, 19, 177.	4.1	7
16	BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. <i>Diagnostic Pathology</i> , 2019, 14, 68.	2.0	41
17	&lt;p&gt;&lt;em&gt;SOX3&lt;/em&gt; methylation correlates with disease progression in patients with chronic myeloid leukemia&lt;p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4789-4794.	2.0	8
18	Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients. <i>BMC Cancer</i> , 2019, 19, 930.	2.6	46

#	ARTICLE	IF	CITATIONS
19	miR-374a-5p: A New Target for Diagnosis and Drug Resistance Therapy in Gastric Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 320-331.	5.1	64
20	Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3295-3304.	2.0	27
21	Establishment and molecular characterization of decitabine-resistant K562 cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3317-3324.	3.6	12
22	MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells. <i>Biomedicine and Pharmacotherapy</i> , 2019, 112, 108623.	5.6	19
23	SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes. <i>Pathology Research and Practice</i> , 2019, 215, 322-328.	2.3	2
24	Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 9438-9446.	4.1	8
25	Low Expression of Pseudogene POU5F1B Affects Diagnosis and Prognosis in Acute Myeloid Leukemia (AML). <i>Medical Science Monitor</i> , 2019, 25, 4952-4959.	1.1	12
26	Promoter methylation of the candidate tumor suppressor gene TCF21 in myelodysplastic syndrome and acute myeloid leukemia. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 3450-3460.	0.0	3
27	Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia. <i>Molecular Carcinogenesis</i> , 2018, 57, 735-744.	2.7	18
28	SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Pathology Research and Practice</i> , 2018, 214, 706-712.	2.3	3
29	Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. <i>Pathology Research and Practice</i> , 2018, 214, 896-901.	2.3	4
30	H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2018, 10, 47.	4.1	79
31	High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. <i>Gene</i> , 2018, 640, 79-85.	2.2	18
32	Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 485-491.	2.3	5
33	Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 3274-3281.	4.1	17
34	TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 5838-5846.	4.1	23
35	Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 4707-4714.	4.1	6
36	Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 2444-2450.	4.1	25

#	ARTICLE	IF	CITATIONS
37	Bone marrow miR-10a overexpression is associated with genetic events but not affects clinical outcome in acute myeloid leukemia. <i>Pathology Research and Practice</i> , 2018, 214, 169-173.	2.3	5
38	Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2018, 16, 135.	4.4	8
39	Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies. <i>Clinical Epigenetics</i> , 2018, 10, 92.	4.1	27
40	Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 9584-9593.	4.1	19
41	<i>CDH1</i> (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 123-131.	2.3	20
42	Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2017, 58, 96-103.	1.3	13
43	Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1853-1864.	2.5	11
44	Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831769912.	1.8	8
45	Epigenetic dysregulation of <i>ID4</i> predicts disease progression and treatment outcome in myeloid malignancies. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1468-1481.	3.6	43
46	<i>GPX3</i> methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. <i>Cancer Medicine</i> , 2017, 6, 267-274.	2.8	22
47	Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia. <i>Journal of Cancer</i> , 2017, 8, 460-468.	2.5	9
48	Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 41498-41507.	1.8	58
49	<i>KRAS</i> overexpression independent of <i>RAS</i> mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 66087-66097.	1.8	34
50	High bone marrow <i>ID2</i> expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 91979-91989.	1.8	11
51	Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 92536-92544.	1.8	13
52	DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 8951-8960.	1.8	15
53	The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 10107-10114.	1.8	20
54	Reduced <i>miR-215</i> expression predicts poor prognosis in patients with acute myeloid leukemia. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 350-356.	1.3	29

#	ARTICLE	IF	CITATIONS
55	BP1overexpression is associated with adverse prognosis inde novoacute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 828-834.	1.3	7
56	Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 491-501.	1.8	6
57	Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0165948.	2.5	10
58	Pseudogene <i>BMI1P1</i> expression as a novel predictor for acute myeloid leukemia development and prognosis. <i>Oncotarget</i> , 2016, 7, 47376-47386.	1.8	13
59	Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation. <i>Oncotarget</i> , 2016, 7, 61419-61425.	1.8	14
60	DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1041-1047.	0.8	4
61	Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1250-1256.	2.1	17
62	The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3. <i>Cancer Biology and Therapy</i> , 2015, 16, 1514-1525.	3.4	3
63	High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia. <i>Tumor Biology</i> , 2015, 36, 9711-9716.	1.8	16
64	Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. <i>Medical Oncology</i> , 2015, 32, 386.	2.5	25
65	MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 127-36.	0.5	4
66	Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2384-91.	0.5	5
67	GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. <i>American Journal of Cancer Research</i> , 2015, 5, 1786-94.	1.4	6
68	The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4321-31.	0.5	4
69	Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5336-44.	0.5	7
70	GPX3 promoter is methylated in chronic myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6450-7.	0.5	10
71	GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. <i>American Journal of Cancer Research</i> , 2015, 5, 2047-55.	1.4	6
72	High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 16073-80.	0.5	7

#	ARTICLE	IF	CITATIONS
73	DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 601-607.	0.8	16
74	Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. <i>Clinical Biochemistry</i> , 2014, 47, 63-66.	1.9	29
75	Methylation of CTNNA1 promoter: Frequent but not an adverse prognostic factor in acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 613-618.	0.8	7
76	Cardiac resynchronization therapy for heart failure induced by left bundle branch block after transcatheter closure of ventricular septal defect. <i>Journal of Geriatric Cardiology</i> , 2014, 11, 357-62.	0.2	4
77	Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2014, 9, e115693.	2.5	25
78	Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1166-71.	0.5	21
79	Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4261-7.	0.5	20
80	Kinetic analysis of the immunity in a pregnant patient infected with avian influenza H7N9. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 1768-74.	1.3	4
81	Decreased SFRP2 expression is associated with intermediate and poor karyotypes in de novo acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4695-703.	0.5	5
82	Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6832-40.	0.5	41
83	Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21). <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8032-8.	0.5	13
84	Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 1642-1647.	0.8	57
85	RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. <i>Clinical Biochemistry</i> , 2013, 46, 579-583.	1.9	60
86	Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 765-768.	0.8	49
87	U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2012, 7, e45760.	2.5	75
88	Aberrant hypomethylation of <i>DDX43</i> promoter in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2012, 158, 293-296.	2.5	9
89	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Annals of Hematology</i> , 2012, 91, 519-525.	1.8	96
90	Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2011, 6, e26906.	2.5	110

#	ARTICLE	IF	CITATIONS
91	Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 783-786.	0.8	12
92	Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. <i>Clinica Chimica Acta</i> , 2010, 411, 2097-2100.	1.1	23
93	Aberrant methylation of the death-associated protein kinase 1 ( <i>DAPK1</i> ) CpG island in chronic myeloid leukemia. <i>European Journal of Haematology</i> , 2009, 82, 119-123.	2.2	43